{
    "ticker": "KMDA",
    "name": "Kamada Ltd.",
    "description": "Kamada Ltd. is a biopharmaceutical company specializing in the development and manufacture of specialty therapeutics that address unmet medical needs. Founded in 1990 and headquartered in Ness Ziona, Israel, Kamada is recognized for its innovative approach to developing therapeutic proteins derived from human plasma, as well as other biologics and complex therapeutics. The company's lead product, Glassia, is the first FDA-approved intravenous alpha-1 antitrypsin (AAT) therapy for patients with AAT deficiency, a genetic condition that can lead to lung and liver disease. In addition to Glassia, Kamada is advancing a robust pipeline of products aimed at treating various respiratory, infectious, and autoimmune diseases. The company is committed to research and development, actively collaborating with strategic partners to enhance its product offerings and expand its market presence globally. Kamada\u2019s mission is to improve patient outcomes through the development of high-quality, innovative treatments that can make a significant difference in the lives of patients suffering from serious medical conditions.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Ness Ziona, Israel",
    "founded": "1990",
    "website": "https://www.kamada.com",
    "ceo": "David Tsur",
    "social_media": {
        "twitter": "https://twitter.com/KamadaLtd",
        "linkedin": "https://www.linkedin.com/company/kamada-ltd/"
    },
    "investor_relations": "https://investors.kamada.com",
    "key_executives": [
        {
            "name": "David Tsur",
            "position": "CEO"
        },
        {
            "name": "Roni Shalev",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Glassia",
                "Kamada AAT"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kamada Ltd. | Innovative Biopharmaceuticals for Serious Conditions",
        "meta_description": "Explore Kamada Ltd., a leader in biopharmaceuticals focused on developing innovative therapies for patients with unmet medical needs. Learn about our products and commitment to healthcare.",
        "keywords": [
            "Kamada",
            "Biopharmaceuticals",
            "Healthcare",
            "Alpha-1 Antitrypsin",
            "Glassia",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Kamada known for?",
            "answer": "Kamada is known for its biopharmaceutical products, particularly Glassia, which is used to treat alpha-1 antitrypsin deficiency."
        },
        {
            "question": "Who is the CEO of Kamada?",
            "answer": "David Tsur is the CEO of Kamada Ltd."
        },
        {
            "question": "Where is Kamada headquartered?",
            "answer": "Kamada is headquartered in Ness Ziona, Israel."
        },
        {
            "question": "What types of products does Kamada offer?",
            "answer": "Kamada offers therapeutics derived from human plasma and other biologics, including Glassia for AAT deficiency."
        },
        {
            "question": "When was Kamada founded?",
            "answer": "Kamada was founded in 1990."
        }
    ],
    "competitors": [
        "BMRN",
        "AMGN",
        "ALNY"
    ],
    "related_stocks": [
        "GILD",
        "REGN",
        "VRTX",
        "ABBV"
    ]
}